Key result
Molecular genetic testing for malignant hyperthermia susceptibility demonstrated a negative predictive value of 0.95 (95% CI 0.75-0.99), necessitating confirmatory IVCT for negative results.
Why the study?
Does molecular genetic testing accurately diagnose malignant hyperthermia susceptibility compared to the in vitro contracture test in individuals undergoing MH testing?
Population
208 individuals undergoing malignant hyperthermia (MH) testing between January 2001 and April 2003
Comparison
Molecular genetic testing vs In vitro contracture test (IVCT)
Design
Cohort
Authors
Loading...
Genetic testing may aid MH diagnosis in select families; leaves open routine clinical use pending higher-level validation.
Observational (n=208)
Does molecular genetic testing accurately diagnose malignant hyperthermia susceptibility compared to the in vitro contracture test in individuals undergoing MH testing?
Effect estimate: NPV 0.95 (95% CI 0.75-0.99)
Molecular genetic testing has a high negative predictive value for malignant hyperthermia susceptibility, but IVCT is still recommended for negative genetic results to ensure patient safety.
Girard et al. (2004) conducted an observational in Malignant hyperthermia susceptibility (n=208). Molecular genetic testing vs. In vitro contracture test (IVCT) was evaluated on Negative predictive value of genetic testing (NPV 0.95, 95% CI 0.75-0.99). Molecular genetic testing for malignant hyperthermia susceptibility demonstrated a negative predictive value of 0.95 (95% CI 0.75-0.99), necessitating confirmatory IVCT for negative results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: